Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Cholinesterase inhibitors in Alzheimer's disease - Are they worth the cost?
Autore:
Whitehouse, PJ;
Indirizzi:
Case Western Reserve Univ, Alzheimer Ctr, Cleveland, OH 44120 USA Case Western Reserve Univ Cleveland OH USA 44120 Cleveland, OH 44120 USA
Titolo Testata:
CNS DRUGS
fascicolo: 3, volume: 11, anno: 1999,
pagine: 167 - 173
SICI:
1172-7047(199903)11:3<167:CIIAD->2.0.ZU;2-0
Fonte:
ISI
Lingua:
ENG
Soggetto:
GUIDELINES; DEMENTIA; TACRINE; CARE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
26
Recensione:
Indirizzi per estratti:
Indirizzo: Whitehouse, PJ Caseveland,n Reserve Univ, Alzheimer Ctr, 12200 Fairhill Rd,Suite C323, Cle Case Western Reserve Univ 12200 Fairhill Rd,Suite C323 Cleveland OH USA 44120
Citazione:
P.J. Whitehouse, "Cholinesterase inhibitors in Alzheimer's disease - Are they worth the cost?", CNS DRUGS, 11(3), 1999, pp. 167-173

Abstract

Several cholinesterase inhibitors have demonstrated their ability to improve cognition in Alzheimer's disease. This paper reviews issues important todetermining whether cholinesterase inhibitors are worth their cost. Establishing therapeutic goals in Alzheimer's disease and assessing initial clinical experience with cholinesterase inhibitors is complex. Measuring impact in daily life activities and clinical significance, including effects on quality of life, will be critical in determining the value of cholinesterase inhibitors. Clearly the current and potential future societal and personal costs of dementia are enormous. Few pharmacoeconomic studies of drug interventions in dementia have been published, and those that have been publishedhave significant limitations. Ethical issues, such as what do we mean by slowing progression of the disease and how do we value this possible outcomeat different stages of the disease will be critical issues to consider further. Determining whose costs and whose quality of life will be affected bythese medications will be a key issue. Initial enthusiasm for cholinesterase inhibitors as a successful application of basic science studies to the treatment of Alzheimer's disease will need to be judged by further outcomes research and dialogue about their costs and value.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/09/20 alle ore 16:09:24